Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10972399 | 0.84 | NNMT (0.60) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL1091971 | 0.79 | MAPT (0.49) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL31670741 | 0.79 | MAPT (0.49) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL6575737 | 0.79 | CA12 (0.53) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL796983 | 0.79 | EPHX2 (0.55) | MAPTL3MBTL1 | |
| SCHEMBL21770762 | 0.79 | SCN1A (0.56) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL659139 | 0.78 | CA12 (0.56) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL29800427 | 0.78 | CA12 (0.56) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL811649 | 0.78 | CA12 (0.56) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL2255952 | 0.78 | PDE4B (0.56) | MAPTCYP1A2PDE4BCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153634-B2 | Carbinol derivatives having cyclic linker | KOWA COMPANY, LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| EP-2281817-A1 | SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER | Kowa Company, Ltd. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | NR1H2, NR1H3, LDLR | MAPT 1455/4885CA12 2793/4885CA1 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.